Continuous VEGF inhibition: a promising treatment strategy
A stable target that is continually expressed
One important question in angiogenesis research is: for how long should inhibition of various pro-angiogenic factors be maintained? As preclinical evidence now suggests, because VEGF is thought to be genetically stable and continuously expressed, it can potentially be targeted throughout tumour development. This section also explores the rationale for continued VEGF inhibition.
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.